Lol, I was being concervative. Like Bio says, the pps doesn't matter because the buyout price will be based on forward earnings. Consider we now have FDA(U.S.) and EMA(Europe) market exclusivity, with a possible fifteen year market exclusivity in the U.S. for unmet medical need. I wouldn't think a buyout price for pc in the $4-$7 range as unrealistic.
With such an outcome, if indeed the trials prove positive and we are blessed with an FDA approval, I'm not even sure anyone here can actually grasp the immensity of such an approval as we'll witness an explosion of volume and urgency of demand for our therapy...globally.
News 
Market Data 
Discover 
